Bicara Therapeutics Announces First Patients Dosed in FORTIFI-HN01 Trial

TipRanksFeb 11 16:45 ET

Express News | Bicara Therapeutics Inc - Primary Endpoints Include Overall Response Rate and Survival

ReutersFeb 11 16:02 ET

Express News | Bicara Therapeutics Inc - Phase 2/3 Trial to Enroll Approximately 650 Patients

ReutersFeb 11 16:02 ET

Express News | Bicara Therapeutics Announces First Patients Enrolled in Fortifi-Hn01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

ReutersFeb 11 16:01 ET

Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

GlobeNewswireFeb 11 16:01 ET

Bicara Therapeutics Initiated at Outperform by Wedbush

Dow JonesFeb 6 08:44 ET · Ratings